Abstract
Background: 5-azacitidine is a very potent chemotherapeutic agent that suffers from certain disadvantages.
Objective: This study aims to prepare gold nanoparticles as a new nano-formula of 5-azacitidine that can improve its bioavailability and decrease its side effects.
Methods: 5-azacytidine-loaded GA-AuNPs were prepared and characterized by UV-Vis spectroscopy, infrared (IR), and electronic transmission microscope (TEM). This new platform was characterized in vitro by measuring its zeta potential, particle size, and drug loading efficacy, and the anti-proliferative effect on the MCF-7 cell line was evaluated. In vivo biodistribution studies of 99mTc-5-aza solution and 99mTc-5-aza-gold nano formula were conducted in tumor-bearing mice by different routes of administration (intravenous and intra-tumor).
Results: 5-Aza-GA-AuNPs formula was successfully prepared with an optimum particle size of ≈34.66 nm, the zeta potential of -14.4 mV, and high entrapment efficiency. 99mTc-5-Aza-GA-AuNPs were successfully radiosynthesized with a labeling yield of 95.4%. Biodistribution studies showed high selective accumulation in tumor and low uptake in non-target organs in the case of the 5-Aza-GA-AuNPs formula than the 99mTc-5-azacitidine solution.
Conclusion: 99mTc-5-Aza-GA-AuNPs improved the selectivity and uptake of 5-azacitidine in cancer. Moreover, 99mTc-5-Aza-GA-AuNPs could be used as hopeful theranostic radiopharmaceutical preparation for cancer.
Keywords: Gold Nanoparticles, Technetium-99m, 5-Azacytidine, Cancer chemotherapeutics, Theranostic radiopharmaceuticals.
[http://dx.doi.org/10.1001/jamaoncol.2019.2996] [PMID: 31560378]
[http://dx.doi.org/10.3322/caac.21590] [PMID: 31912902]
[http://dx.doi.org/10.1016/j.ejps.2012.12.006] [PMID: 23262059]
[http://dx.doi.org/10.1016/j.lungcan.2003.12.010] [PMID: 15140551]
[http://dx.doi.org/10.3857/roj.2021.00815] [PMID: 34986552]
[http://dx.doi.org/10.1016/j.apradiso.2020.109269] [PMID: 32819507]
[http://dx.doi.org/10.1007/s13187-019-1469-2] [PMID: 30637532]
[http://dx.doi.org/10.1016/j.addr.2015.12.012] [PMID: 26712711]
[http://dx.doi.org/10.1007/s00216-005-0247-7] [PMID: 16440195]
[http://dx.doi.org/10.3390/ijms21124412] [PMID: 32575884]
[http://dx.doi.org/10.1021/acs.molpharmaceut.8b00810] [PMID: 30452861]
[http://dx.doi.org/10.1186/s12645-016-0021-x] [PMID: 27867425]
[http://dx.doi.org/10.1039/D0CS01121E] [PMID: 33089858]
[http://dx.doi.org/10.3390/pharmaceutics12080701] [PMID: 32722426]
[http://dx.doi.org/10.1039/C1NR11188D] [PMID: 22076024]
[http://dx.doi.org/10.2217/nnm.10.113] [PMID: 21128723]
[http://dx.doi.org/10.4314/tjpr.v13i7.23]
[http://dx.doi.org/10.1016/j.addr.2013.09.006] [PMID: 24060923]
[http://dx.doi.org/10.3390/biom12010071] [PMID: 35053219]
[http://dx.doi.org/10.5114/aoms/144119]
[http://dx.doi.org/10.1016/j.biomaterials.2007.12.037] [PMID: 18242692]
[http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID: 30231877]
[http://dx.doi.org/10.1016/j.pdpdt.2017.12.004] [PMID: 29223737]
[http://dx.doi.org/10.1021/jp209251y]
[http://dx.doi.org/10.3390/molecules25010204] [PMID: 31947834]
[http://dx.doi.org/10.1039/b9nr00112c] [PMID: 20644861]
[http://dx.doi.org/10.1039/b816209c]
[http://dx.doi.org/10.3390/app9163232]
[http://dx.doi.org/10.1016/j.reffit.2017.03.002]
[http://dx.doi.org/10.1002/smll.201303507] [PMID: 24777891]
[http://dx.doi.org/10.1016/j.biomaterials.2016.08.048] [PMID: 27619241]
[http://dx.doi.org/10.15171/apb.2016.048] [PMID: 27766220]
[http://dx.doi.org/10.1002/ijc.23607] [PMID: 18425818]
[http://dx.doi.org/10.3390/ph5080875] [PMID: 24280679]
[http://dx.doi.org/10.1016/j.tiv.2011.12.018] [PMID: 22245431]
[http://dx.doi.org/10.1016/j.micromeso.2016.10.041]
[http://dx.doi.org/10.1002/jlcr.3839] [PMID: 32220029]
[http://dx.doi.org/10.1021/acs.bioconjchem.6b00437] [PMID: 27547843]
[http://dx.doi.org/10.1016/j.ijpharm.2020.119514] [PMID: 32565281]
[http://dx.doi.org/10.1007/s13404-013-0122-9]
[http://dx.doi.org/10.4172/2157-7439.1000133]
[http://dx.doi.org/10.1016/B978-0-12-411636-8.00001-8] [PMID: 23954098]
[http://dx.doi.org/10.1016/j.xphs.2021.03.021] [PMID: 33812886]
[http://dx.doi.org/10.4236/ojmc.2018.82002]
[http://dx.doi.org/10.1016/j.apradiso.2009.10.030] [PMID: 19900818]
[http://dx.doi.org/10.1016/j.apradiso.2012.06.007] [PMID: 22871442]
[http://dx.doi.org/10.1002/jlcr.3952] [PMID: 34582054]
[http://dx.doi.org/10.3390/pharmaceutics12020107] [PMID: 32013203]
[http://dx.doi.org/10.1016/j.ejps.2018.06.029] [PMID: 29981892]
[http://dx.doi.org/10.1007/s11547-016-0677-7] [PMID: 27586132]
[http://dx.doi.org/10.1007/s10967-014-3233-8]
[http://dx.doi.org/10.3390/molecules23020496] [PMID: 29473879]
[http://dx.doi.org/10.1111/cbdd.13393] [PMID: 30216686]
[http://dx.doi.org/10.3389/fbioe.2020.00990] [PMID: 32903562]
[http://dx.doi.org/10.1155/2012/813958]
[http://dx.doi.org/10.1016/S0021-9673(01)87101-6] [PMID: 2422189]
[http://dx.doi.org/10.1016/j.materresbull.2015.12.026]
[http://dx.doi.org/10.1016/j.jconrel.2014.03.053] [PMID: 24747160]
[http://dx.doi.org/10.2147/IJN.S132780] [PMID: 28615938]
[http://dx.doi.org/10.1098/rstb.2013.0099] [PMID: 24493747]
[http://dx.doi.org/10.1016/j.colsurfb.2011.02.033] [PMID: 21439797]
[http://dx.doi.org/10.1016/j.tranon.2020.100839] [PMID: 32763504]
[http://dx.doi.org/10.2147/IJN.S279094] [PMID: 33324054]
[http://dx.doi.org/10.1016/j.tiv.2010.04.009] [PMID: 20417267]
[http://dx.doi.org/10.1208/s12248-020-00464-x] [PMID: 32495039]
[http://dx.doi.org/10.1002/smll.201907574] [PMID: 32250017]
[http://dx.doi.org/10.1021/la401192x] [PMID: 23631648]
[http://dx.doi.org/10.1007/s00277-010-1015-0] [PMID: 20567826]
[http://dx.doi.org/10.1016/j.leukres.2006.03.003] [PMID: 16620971]
[http://dx.doi.org/10.1248/bpb.23.1153] [PMID: 11041242]
[PMID: 29599323]
[http://dx.doi.org/10.1016/j.taap.2020.114996] [PMID: 32278510]
[http://dx.doi.org/10.1016/j.msec.2019.04.034] [PMID: 31146983]
[http://dx.doi.org/10.1016/j.nucmedbio.2012.08.010] [PMID: 23146307]